Cargando…

New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil

Renin–angiotensin–system (RAS) activation plays a key role in the development of hypertension and cardiovascular disease. Drugs that antagonize the RAS (angiotensin-converting enzyme [ACE] inhibitors and angiotensin receptor blockers [ARBs]) have proven clinical efficacy in reducing blood pressure v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Volpe, Massimo, Savoia, Carmine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308687/ https://www.ncbi.nlm.nih.gov/pubmed/22457601 http://dx.doi.org/10.2147/IBPC.S13784

Ejemplares similares

Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy
por: Angeloni, Emiliano
Publicado: (2016)

Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension
por: Weber, Michael A., et al.
Publicado: (2014)

Exploring the Effectiveness and Safety of Azilsartan-Medoxomil/Chlorthalidone Versus Olmesartan-Medoxomil/Hydrochlorothiazide in Hypertensive Patients: A Meta-Analysis
por: Kumar, Lakshya, et al.
Publicado: (2023)

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
por: Juhasz, Attila, et al.
Publicado: (2018)

Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension
por: Johnson, Wallace, et al.
Publicado: (2017)

Safety, Tolerability, and Efficacy of Azilsartan Medoxomil With or Without Chlorthalidone During and After 8 Months of Treatment for Hypertension
por: Kipnes, Mark S., et al.
Publicado: (2015)

A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients with Essential Hypertension and Type 2 Diabetes in Asia
por: Deerochanawong, Chaicharn, et al.
Publicado: (2022)

Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults
por: Webb, Nicholas J. A., et al.
Publicado: (2016)

Efficacy and Safety of Azilsartan Medoxomil and Telmisartan in Hypertensive Patients: A Randomized, Assessor-Blinded Study
por: Garg, Megha, et al.
Publicado: (2020)

Spectrophotometric and Spectrofluorimetric Studies on Azilsartan Medoxomil and Chlorthalidone to Be Utilized in Their Determination in Pharmaceuticals
por: Ebeid, Walid M, et al.
Publicado: (2014)

A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone
por: Weber, Michael A, et al.
Publicado: (2018)

Olmesartan medoxomil for the treatment of hypertension in children and adolescents
por: Tocci, Giuliano, et al.
Publicado: (2011)

Efficacy and safety of different doses of azilsartan medoxomil in patients with hypertension: A protocol of a network meta-analysis
por: Zhang, Yan, et al.
Publicado: (2019)

Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study
por: Handley, Alison, et al.
Publicado: (2016)

Use of azilsartan medoxomil in the primary-care setting in Germany: A real-world evidence study
por: Ehlken, Birgit, et al.
Publicado: (2019)

Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril
por: Bönner, G, et al.
Publicado: (2013)

Effects of Age, Sex, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of Azilsartan Medoxomil in Healthy Subjects
por: Harrell, Robert E., et al.
Publicado: (2015)

Effects of Food Intake on the Pharmacokinetics of Azilsartan Medoxomil and Chlorthalidone Alone and in Fixed‐Dose Combination in Healthy Adults
por: Dudkowski, Caroline, et al.
Publicado: (2016)

A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension
por: Wu, Jiahui, et al.
Publicado: (2020)

A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension
por: Cushman, William C., et al.
Publicado: (2018)

A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension: Erratum
Publicado: (2020)

Azilsartan: Current Evidence and Perspectives in Management of Hypertension
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes
por: White, William B., et al.
Publicado: (2016)

Single‐Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment
por: Dudkowski, Caroline, et al.
Publicado: (2017)

Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
por: Greathouse, Mark
Publicado: (2006)

Clinical utility of azilsartan–chlorthalidone fixed combination in the management of hypertension
por: Shuster, Jerrica E, et al.
Publicado: (2012)

Central Composite Design Implemented Azilsartan Medoxomil Loaded Nanoemulsion to Improve Its Aqueous Solubility and Intestinal Permeability: In Vitro and Ex Vivo Evaluation
por: Kumar, Girish, et al.
Publicado: (2022)

Efficacy and Safety of Azilsartan and Telmisartan in Hypertensive Patients
por: Kumar, Alok, et al.
Publicado: (2021)

Is the newest angiotensin‐receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta‐analysis
por: Wang, Ji‐Guang, et al.
Publicado: (2021)

Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications
por: Gallo, Giovanna, et al.
Publicado: (2022)

Design of Olmesartan Medoxomil-Loaded Nanosponges for Hypertension and Lung Cancer Treatments
por: Almutairy, Bjad K., et al.
Publicado: (2021)

Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals
por: Basile, Jan
Publicado: (2010)

The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry
por: Bramlage, Peter, et al.
Publicado: (2015)

Personalized medicine—a modern approach for the diagnosis and management of hypertension
por: Savoia, Carmine, et al.
Publicado: (2017)

Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
por: Punzi, Henry A
Publicado: (2011)

EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry
por: Gitt, Anselm K, et al.
Publicado: (2013)

Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies
por: Tini, Giacomo, et al.
Publicado: (2023)

New treatment options for fibromyalgia: critical appraisal of duloxetine
por: Üçeyler, Nurcan, et al.
Publicado: (2008)

Critical evaluation of the efficacy and tolerability of azilsartan
por: De Caterina, Alberto R, et al.
Publicado: (2012)

Small bowel enteropathy associated with olmesartan medoxomil treatment
por: Galanopoulos, Michail, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c4cj5uhphvpgfi0fui6tke5cl6